Bernstein Upgrades Biomarin Pharmaceutical to Market Perform, Announces $82 Price Target
Portfolio Pulse from Benzinga Newsdesk
Bernstein analyst William Pickering has upgraded Biomarin Pharmaceutical (NASDAQ:BMRN) from Underperform to Market Perform and set a price target of $82.
October 23, 2023 | 9:21 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biomarin Pharmaceutical has been upgraded by Bernstein from Underperform to Market Perform with a new price target of $82.
The upgrade from Underperform to Market Perform by Bernstein indicates a positive change in the company's outlook. The new price target of $82 also suggests potential upside for the stock. This could lead to increased investor interest and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100